Maximal response to electroconvulsive therapy for the treatment of catatonic symptoms

Journal of ECT

Volumn 23, Issue 4, 2007, Pages 233-235

  Hatta, Kotaro ^a   Miyakawa, Koichi ^a   Ota, Tsuneyoshi ^a   Usui, Chie ^a   Nakamura, Hiroyuki ^b   Arai, Heii ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Benzodiazepine; Chlorpromazine; Haloperidol; Risperidone; Stupor

Indexed keywords

ATROPINE; BENZODIAZEPINE; CHLORPROMAZINE; DIAZEPAM; FLUNITRAZEPAM; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; RISPERIDONE;

ACUTE LARYNGEAL DYSTONIA; ARTICLE; CATATONIA; CLINICAL ARTICLE; CREATINE KINASE BLOOD LEVEL; DYSTONIA; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; HOSPITAL ADMISSION; HUMAN; LIVER DYSFUNCTION; SIDE EFFECT; STUPOR; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CATATONIA; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCONVULSIVE THERAPY; FEMALE; HALOPERIDOL; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; LORAZEPAM; MALE; MIDDLE AGED; RETREATMENT; RISPERIDONE; SCHIZOPHRENIA, CATATONIC; TREATMENT OUTCOME;

EID: 37349052747     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/yct.0b013e3181587949     Document Type: Article

References (18)

1. Bush G, Fink M, Petrides G, et al. Catatonia II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand. 1996;93:137-143.
2. Taylor M-A, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry. 2003;160:1233-1241.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision; DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
4. Ahuja N. Organic catatonia: a review. Ind J Psychiatry. 2000;42:327-346.
5. Hawkins J-M, Archer K-J, Strowski S-M, et al. Somatic treatment of catatonia. Int J Psychiatry Med. 1995;25:345-369.
6. Hermesh H, Aizenberg D, Weizman A, et al. Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients. Br J Psychiatry. 1992;161:254-257.
7. Keck P-E, Pope H-G, Cohen B-M, et al. Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry. 1989;46:914-918.
8. White D-A-C, Robins A-H. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry. 1991;158:419-421.
9. Cook E-H, Olson K, Pliskin N. Response of organic catatonia to risperidone. Arch Gen Psychiatry. 1996;53:82-83.
10. Hesslinger B, Walden J, Normann C. Acute and long-term treatment of catatonia with risperidone. Pharmacopsychiatry. 2001;34:25-26.
11. Marneros A, Jager A. Treatment of catatonic stupor with oral lorazepam in 14-year-old psychotic boy. Pharmacopsychiatry. 1993;26:259-260.
12. Ungvari G-S, Leung H-C, Lee T-S. Benzodiazepines and the psychopathology of catatonia. Pharmacopsychiatry. 1994;27:242-245.
13. Fink M, Taylor MA. Catatonia: A Clinician's Guide to Diagnosis, and Treatment. Cambridge, UK: Cambridge University Press; 2003.
14. Ungvari G-S, Kau L-S, Wai-Kwong T, et al. The pharmacological treatment of catatonia: an overview. Eur Arch Psychiatry Clin Neurosci. 2001;251:(suppl 1):31-34.
15. Rosebush P-I, Hildebrand A-M, Furlong B-G, et al. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry. 1990;51:357-362.
16. Beckmann H, Fritze J, Franzek E. The influence of neuroleptics on specific syndromes and symptoms in schizophrenics with unfavourable long-term course. Neuropsychobiology. 1992;26:50-58.
17. De Pauw K-W, Szulecka T-K. Lucid intervals in catatonia: a neuropsychiatric snare for the unwary. Br J Psychiatry. 1987;151:561-562.
18. Ainaworth P. A case of 'lethal catatonia' in a 14-year-old girl. Br J Psychiatry. 1987;150:110-112.